Balanced news tone
News Sentiment
GTBP sentiment intelligence
GT Biopharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
58 relevant articles
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-16.3% over one week, -30.8% over four weeks, trend inactive, and below fair value.
Price to earnings forward of GT Biopharma, Inc. – NASDAQ:GTBP
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
81/100 classification
One-week reaction
-16.3%
Price reacting lower
Trend fit
Trend inactive
-30.8% over four weeks
Fair value
-88.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
9
Neutral
46
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
dars.gov.et
Direct company coverage
GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment Weakens - Ichimoku Kumo Twist
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- dars.gov.et
Investing.com
Direct company coverage
GT Biopharma receives 180-day extension from Nasdaq to meet minimum bid price
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 07:00
- Source
- Investing.com
GlobeNewswire
Direct company coverage
GT Biopharma Reports First Quarter 2026 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 12:00
- Source
- GlobeNewswire
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
GlobeNewswire
Direct company coverage
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 12:30
- Source
- GlobeNewswire
Benzinga
Direct company coverage
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 12:16
- Source
- Benzinga
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Quiver Quantitative
Direct company coverage
GTBP | GT Biopharma Inc. Common Insider Trading
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 14:33
- Source
- Quiver Quantitative
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know
- Tone
- Positive 84/100
- Event
- Analyst action
- Published
- 16 Mar 2026 07:00
- Source
- Market source
Zacks Investment Research
Direct company coverage
Should I buy GT Biopharma (GTBP)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 Mar 2026 07:00
- Source
- Zacks Investment Research
Market source
Direct company coverage
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Mar 2026 07:00
- Source
- Market source
Market source
Direct company coverage
GT Biopharma Reports Full Year 2025 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Mar 2026 08:00
- Source
- Market source
Market source
Direct company coverage
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Nov 2025 08:00
- Source
- Market source
Stocktwits
Direct company coverage
GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Oct 2025 07:00
- Source
- Stocktwits
Market source
Direct company coverage
EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Oct 2025 07:00
- Source
- Market source
Stocktwits
Direct company coverage
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Feb 2025 02:14
- Source
- Stocktwits
Investing.com
Direct company coverage
GT Biopharma faces Nasdaq delisting over equity shortfall
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Nov 2024 08:00
- Source
- Investing.com
InvestorPlace
Direct company coverage
Why Is GT Biopharma (GTBP) Stock Up 143% Today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2024 07:00
- Source
- InvestorPlace
Zacks Investment Research
Direct company coverage
What is the current Price Target and Forecast for GT Biopharma (GTBP)
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 03 Mar 2023 06:05
- Source
- Zacks Investment Research
TradingView
Direct company coverage
GTBP Stock Price and Chart — NASDAQ:GTBP
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Feb 2021 15:39
- Source
- TradingView
StockInvest.us
Direct company coverage
Gt Biopharma Stock Price Forecast. Should You Buy GTBP?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 01 Dec 2020 12:13
- Source
- StockInvest.us
Zacks Investment Research
Direct company coverage
GT Biopharma (GTBP)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Nov 2017 23:17
- Source
- Zacks Investment Research
Yahoo! Finance Canada
Direct company coverage
GT Biopharma, Inc. (GTBP) Stock Price, News, Quote & History
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Sep 2017 12:35
- Source
- Yahoo! Finance Canada